Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXTAC-III anamorelin plus nutrition and exercise in elderly patients with cancer cachexia
jRCTs041210053Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anamorelin in cancer anorexia-cachexia syndrome (CACS), non-small cell lung cancer (NSCLC) and pancreatic cancer (PC) (2 arms), sponsored by Japan Agency for Medical Research and Development. Started Nov 2021; status: active, not recruiting.
02
Drugs
anamorelin
03
Conditions
cancer anorexia-cachexia syndrome (CACS)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs041210053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210053.